Fraunhofer Institute for Cell Therapy and Immunology IZI

Fraunhofer IZI honors institute founder with symposium

Press release | September 28, 2018

more info

Fraunhofer IZI and Novartis Continue Successful Collaboration with CAR-T Cell Therapy

Press release | August 31, 2018

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering.

One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology.

Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation.

In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career

Press

Publications

News

 

Press information / 28.9.2018

Fraunhofer IZI honors institute founder with symposium

This year’s Fraunhofer Life Science Symposium was held on September 27, 2018 in honor of institute founder Professor Frank Emmrich. Professor Emmrich set up the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig back in 2005. In December 2017, after 13 years of success and strong growth, he handed over the reins to Professor Ulrike Köhl.

 

Press information / 31.8.2018

Fraunhofer IZI and Novartis Continue Successful Collaboration with CAR-T Cell Therapy

Novartis and Fraunhofer IZI announced today that a further agreement has been concluded between Novartis and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig for the manufacture of the CAR (chimeric antigen receptor)-T cell therapy for patients in Europe over the next few years. The collaboration that began back in 2015 to manufacture CAR-T cell therapies for patients taking part in clinical trials initiated by Novartis is therefore being successfully expanded and continued.

Press information / 29.6.2018

Optimising self-assembling molecular structures for use in diagnostics applications

Researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI, Harvard University and the University of Cambridge probing the mysteries of how DNA molecules can self-assemble into complex structures have found ways of tuning the assembly process to make it more efficient and significantly faster.

 

Press information / 19.6.2018

Non-human papillomaviruses as gene shuttle

Nucleic acids such as DNA and RNA are being drawn upon more and more in modern medicine, with  gene sequences, for instance, being applied in gene therapies and DNA vaccines. The latter of these offer multiple advantages compared with traditional vaccination methods as they are quick to manufacture, easy to adapt and are highly stable. Moreover, the coded antigens are produced by the body itself, meaning they are correctly modified and/or folded. Immunization using DNA vaccines activates both the cellular and the humoral immune defense, i.e. the production of antibodies by the B-lymphocytes, thus helping to provide effective protection against pathogens.

 

 

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000
E-mail info@izi.fraunhofer.de

 

 

Social Media